The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Options & Total Voting Rights

28 Apr 2021 09:47

RNS Number : 8677W
Byotrol PLC
28 April 2021
 

 

 

 

 

Byotrol Plc

 

("Byotrol" or the "Group")

 

Exercise of Options and Total Voting Rights

 

 

Byotrol plc (AIM: BYOT), the anti-microbial technology company, announces that it has allotted a total of 6,765,000 new ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") following the exercise of 6,540,000 options by certain Directors and 225,000 by certain employees below Board level. Of these, 5,965,000 options were reaching maturity and were due to expire in the current calendar year.

 

All 6,540,000 of the Ordinary Shares issued to the Directors below were subsequently sold at a price of 6.92p. The details of those exercised and sold by such Directors is below:

 

 

Director

Total number of share options exercised

Number of Ordinary Shares sold

Resultant Shareholding

Percentage of the Company's issued share capital held

Remaining number of options held

David Traynor

2,360,000

2,360,000

9,691,142

2.14

2,710,000

Nic Hellyer

800,000

800,000

629,870

0.14

1,200,000

John Langlands

2,700,000

2,700,000

9,000,000

1.99

Nil

Dr Trevor Francis

680,000

680,000

4,470,214

0.99

4,730,000

 

Application has been made for the 6,765,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 5 May 2021.

 

After Admission, the total number of Ordinary Shares in issue will be 453,295,405 and the total number of voting rights will therefore be 453,295,405. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

 

For further information contact:

 

Byotrol Plc

David Traynor, Chief Executive

+44 (0)1925 742 000

Nic Hellyer, Chief Financial Officer

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/Kate Bannatyne - Corporate Finance

Richard Chambers - ECM

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

 

byotrol@flagstaffcomms.com

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Traynor

2. 

Reason for the Notification. 

a)

Position/status

CEO

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol plc

b)

LEI

213800AJMTSTIPA59A34

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Options over Ordinary Shares

Ordinary Shares

Identification code

GB00B0999995

b)

Nature of the transaction

 

Exercise of Options

Sale of Ordinary shares

c)

Price(s) and volume(s)

Exercise Price

Volume(s)

3.50p

360,000

4.125p

2,000,000

 

Sale Price(s)

Volume(s)

6.92p

2,000,000

6.92p

360,000

d)

Aggregated information:

· Aggregated volume

· Price

 

As above

e)

Date of the transaction

27 April 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Nic Hellyer

2. 

Reason for the Notification. 

a)

Position/status

CFO

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol plc

b)

LEI

213800AJMTSTIPA59A34

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Options over Ordinary Shares

Ordinary Shares

Identification code

GB00B0999995

b)

Nature of the transaction

 

Exercise of Options

Sale of Ordinary shares

c)

Price(s) and volume(s)

Exercise Price

Volume(s)

2.60p

800,000

 

Sale Price(s)

Volume(s)

6.92p

800,000

d)

Aggregated information:

· Aggregated volume

· Price

 

As above

e)

Date of the transaction

27 April 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Langlands

2. 

Reason for the Notification. 

a)

Position/status

Non-Executive Chairman

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol plc

b)

LEI

213800AJMTSTIPA59A34

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Options over Ordinary Shares

Ordinary Shares

Identification code

GB00B0999995

b)

Nature of the transaction

 

Exercise of Options

Sale of Ordinary shares

c)

Price(s) and volume(s)

Exercise Price

Volume(s)

4.125p

2,700,000

 

Sale Price(s)

Volume(s)

6.92p

2,700,000

d)

Aggregated information:

· Aggregated volume

· Price

 

As above

e)

Date of the transaction

27 April 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dr Trevor Francis

2. 

Reason for the Notification. 

a)

Position/status

Chief Technology Officer

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol plc

b)

LEI

213800AJMTSTIPA59A34

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Options over Ordinary Shares

Ordinary Shares

Identification code

GB00B0999995

b)

Nature of the transaction

 

Exercise of Options

Sale of Ordinary shares

c)

Price(s) and volume(s)

Exercise Price

Volume(s)

3.50p

180,000

4.125p

500,000

 

Sale Price(s)

Volume(s)

6.92p

180,000

6.92p

500,000

d)

Aggregated information:

· Aggregated volume

· Price

 

As above

e)

Date of the transaction

27 April 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRDKFBQFBKKNQB
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.